Partnership formed for vision restoration

Article

The Max Planck Society (Max-Planck-Gesellschaft) and Fovea Pharmaceuticals (the ophthalmology division of Sanofi) have announced the formation of a partnership to identify and develop innovative solutions for restoring vision in patients suffering from diseases affecting the retina.

The Max Planck Society (Max-Planck-Gesellschaft) and Fovea Pharmaceuticals (the ophthalmology division of Sanofi) have announced the formation of a partnership to identify and develop innovative solutions for restoring vision in patients suffering from diseases affecting the retina.

This research collaboration and licence agreement will last for 3 years and will see the Fovea team work with the Max Planck Institute of Biophysics, led by Professor Ernst Bamberg, who pioneered the understanding of the application of retinal binding channelrhodopsins and was one of the founders of optogenetics. Professor Bamberg commented, "The cooperation is a big step forward to bring the optogenetic approach to the clinics."

The agreement will complement other collaborations of Fovea and will further advance research on the retinal binding protein channelrhodopsin 2 (ChR2) and its application in retinal diseases. It is hoped that a successful outcome of this research will result in restoration of visual function in patients suffering from reduced vision or blindness.

Under the terms of the agreement the Max Planck Institute will receive a total of €450,000 and Sanofi will be given priority access to the technology, inventions and derived technologies of the Max Planck Institute research activities in ChR2.

For more information visit the Max Planck Society's website at www.mpg.de

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.